Clinical Trial Update: A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the efficacy and safety of CP-690,550 (tofacitinib) for moderate to severe chronic plaque psoriasis has completed. Results have been po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• CP-690,550 (tofacitinib) (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2014-09-19